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Diesters of phthalic acid (phthalates) and phe­
nols are found in many consumer products. 
Low molecular weight (MW) phthalates (MW 
< 250 g/mol) are used in personal care prod­
ucts (perfumes, cosmetics) or as coating for 
pharmaceutical products. High MW phtha­
lates (MW > 250 g/mol) tend to be used in 
polyvinylchloride floor and wall covering, food 
packaging, and medical devices (Calafat et al. 
2006; Hauser and Calafat 2005). Phenols are 
used in food packaging [bisphenol A, (BPA)], 
polycarbonates (BPA), cosmetics (parabens), 
soap [triclosan (TCS)], and sunscreen [benzo­
phenone­3 (BP3)] (Calafat et al. 2008). 
Precursors of dichlorophenols (DCPs) are 
used as intermediates in the production of 
several herbicides or insecticides (Agency for 
Toxic Substances and Disease Registry 2006).
Widespread exposure to phthalates and 
phenols has been documented for preg­
nant women in several industrialized coun­
tries (Adibi et al. 2008; Braun et al. 2011; 
Cantonwine et al. 2010; Wolff et al. 2008; 
Ye et al. 2008, 2009). Some of these com­
pounds can cross the placenta in humans 
(Balakrishnan et al. 2010; Mose et al. 2007), 
and phthalates have been detected in cord 
blood (Latini et al. 2003), amniotic fluid 
(Huang et al. 2009; Silva et al. 2004), and 
meconium (Zhang et al. 2009).
Little is known about the consequences of 
prenatal exposures to phthalates and phenols on 
fetal growth. An American cohort study of 404 
mother–infant pairs reported an inverse associa­
tion for 2,5­DCP maternal urinary concentra­
tions and a positive association for BP3 urinary 
concentrations with birth weight in male but 
not in female newborns (Wolff et al. 2008).
Our aim was to study the relationships 
between prenatal exposures to phthalates and 
phenols and weight, length, and head circum­
ference at birth among male newborns.
Population and Methods
Study population. We conducted a case–
control study of male malformations of the 
genitalia nested in the EDEN (Etude des 
Déterminants pré et post natals du développe­
ment et de la santé de l’Enfant) and PELAGIE 
mother–child cohorts. These cohorts are 
described elsewhere (Drouillet et al. 2009; 
Garlantezec et al. 2009). Briefly, the EDEN 
cohort consists of 2,002 pregnant women 
recruited before the end of the 28th gestational 
week from April 2003 through March 2006 in 
the obstetrical departments of the University 
Hospitals of Nancy and Poitiers, France. The 
PELAGIE cohort consists of 3,421 pregnant 
women enrolled before 19 weeks of gesta­
tion from April 2002 through February 2006 
in three districts of Brittany: Ille et Vilaine, 
Finistère, and Côtes d’Armor, France. The 
present study includes all of the male new­
borns with undescended testis or hypospadias 
(identified at birth by pediatricians; n = 48 
in EDEN and 24 in PELAGIE). In addi­
tion, three male newborns without congenital 
malformation of the genitalia (controls) were 
matched to each case by recruitment center, 
date of recruitment (± 6 months), day of week 
(weekend yes/no), and gestational week when 
the maternal urine sample was collected, for a 
total of 288 mother–newborn pairs (72 cases 
and 216 controls). Participants provided 
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Ba c k g r o u n d: Data concerning the effects of prenatal exposures to phthalates and phenols on fetal 
growth are limited in humans. Previous findings suggest possible effects of some phenols on male 
birth weight.
oB j e c t i v e: Our aim was to assess the relationships between prenatal exposures to phthalates and 
phenols and fetal growth among male newborns.
Me t h o d s : We conducted a case–control study on male malformations of the genitalia nested in 
two French mother–child cohorts with recruitment between 2002 and 2006. We measured, in 
maternal urinary samples collected between 6 and 30 gestational weeks, the concentrations (micro-
grams per liter) of 9 phenol (n = 191 pregnant women) and 11 phthalate metabolites (n = 287). 
Weight, length, and head circumference at birth were collected from maternity records. Statistical 
analyses were corrected for the oversampling of malformation cases.
re s u l t s: Adjusted birth weight decreased by 77 g [95% confidence interval (CI): –129, –25] and by 
49 g (95% CI: –86, –13) in association with a 1-unit increase in ln-transformed 2,4-dichlorophenol 
(DCP) and 2,5-DCP urinary concentrations, respectively. Benzophenone-3 (BP3) ln-transformed 
concentrations were positively associated with weight (26 g; 95% CI: –2, 54) and head circumfer-
ence at birth (0.1 cm; 95% CI: 0.0, 0.2). Head circumference increased by 0.3 cm (95% CI: 0.0, 
0.7) in association with a 1-unit increase in ln-transformed BPA concentration. For phthalate 
metabolites there was no evidence of monotonic associations with birth weight.
co n c l u s i o n s: Consistent with findings of a previous study, we observed evidence of an inverse 
association of 2,5-DCP and a positive association of BP3 with male birth weight.
key w o r d s : birth outcomes, fetal growth, phenols, phthalates, pregnancy exposure, urinary bio-
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informed consent for data and biological sam­
ple collection for themselves and their off­
spring. These cohorts received the approvals 
of the appropriate ethical committees. The 
involvement of the Centers for Disease 
Control and Prevention (CDC) laboratory 
was limited and determined not to constitute 
engagement in human subjects research.
Outcomes. We extracted from hospital 
maternity records weight, length, and head 
circumference assessed at birth.
Exposure assessment. Urine was col­
lected between 6 and 19 gestational weeks in 
the PELAGIE cohort and between 24 and 
30 gestational weeks in the EDEN cohort. 
Assessment of biomarker and creatinine con­
centrations in maternal urine was done by the 
National Center for Environmental Health 
laboratory at the CDC in Atlanta, Georgia, 
USA (Silva et al. 2007; Ye et al. 2005). We 
measured the urinary concentrations of 
11 phthalate metabolites in samples from all 
mothers (n = 287; 72 cases and 215 controls 
because the vial of one control broke dur­
ing transport to the CDC laboratory). Nine 
phenols were measured in urine samples col­
lected from mothers in the EDEN cohort only 
(n = 191; 48 cases and 143 controls) (phe­
nols could not be measured in the PELAGIE 
cohort because a preservative added to the 
samples interferes with the assay used).
Molar concentrations of four metabo­
lites of di(2­ethylhexyl) phthalate (DEHP) 
[mono(2­ethylhexyl) phthalate (MEHP); 
mono(2­ethyl­5­hydroxyhexyl) phthalate 
(MEHHP); mono(2­ethyl­5­oxohexyl) phtha­
late (MEOHP); and mono(2­ethyl­5­carboxy­
pentyl) phthalate (MECPP)] were summed 
as total DEHP. Concentrations of phthalate 
metabolites of MW > 250 g/mol and of MW 
< 250 g/mol were summed as total of high 
MW phthalates (∑HMW) and of low MW 
phthalates (∑LMW), respectively. Total para­
ben concentration (∑PB) was calculated by 
summing methyl paraben (MP), ethyl paraben 
(EP), propyl paraben (PP), and butyl paraben 
(BP) molar concentrations. Monoethyl phtha­
late (MEP) and monobenzyl phthalate (MBzP) 
concentrations have been corrected [multiplied 
by 0.66 (MEP) and 0.72 (MBzP)] because the 
analytical standards used were of inadequate 
purity (Calafat AM, personal communication).
Statistical analyses. We replaced concen­
trations below the limit of detection (LOD) 
by LOD/√
–
2. We corrected the overrepresen­
tation of congenital abnormalities, induced 
by the case–control design, using a reweight­
ing approach. We used center­specific weights 
corresponding to the inverse of the inclusion 
probability of controls, so as to give cases 
and controls the same relative weight as in 
the original cohorts (Richardson et al. 2007). 
Sensitivity analyses restricted to controls were 
also conducted.
To limit the impact of between­subject 
variations in urine sampling conditions, we 
standardized biomarker concentrations using 
a two­step standardization method based on 
regression residuals. First, we estimated asso­
ciations between ln­transformed biomarker 
concentrations and sampling conditions [hour 
of sampling (for EDEN only), gestational age 
at collection, duration of storage at room tem­
perature before freezing, and season and day of 
sampling] using separate linear regression mod­
els for each biomarker adjusted for maternal 
age, body mass index (BMI) before pregnancy, 
parity, year of sampling, education, current 
occupation, active smoking, and center. Next, 
we used these data to estimate biomarker con­
centrations that would have been observed if 
all samples had been collected under the same 
conditions (e.g., 0730 hours for hour of sam­
pling). Unless otherwise specified, all concen­
trations are the standardized values; we also 
report associations with biomarker concentra­
tions not standardized for sampling conditions.
Associations between each standardized 
maternal urinary biomarker concentration and 
birth weight, birth length, or head circumfer­
ence were estimated using separate weighted 
linear regressions. Biomarker concentrations 
(micrograms per liter) were ln­transformed 
or coded in tertiles. We performed tests of 
hetero  geneity in outcome value across expo­
sure tertiles; p­values of trend tests were esti­
mated using categorical variables whose values 
corresponded to the tertile­specific median 
biomarker levels. Situations in which biomark­
ers exhibited heterogeneity in outcome across 
tertiles (low p­value, heterogeneity test) but 
with little support for a trend (high p­value, 
trend test) were considered as suggestive of 
a nonmonotonic association. [A monotonic 
trend does not reverse direction but may have 
flat segment (Rothman et al. 2008).] We also 
estimated adjusted relationships between stan­
dardized biomarker concentrations and birth 
weight using restricted cubic splines (Harrell 
2001). Adjustment factors were all variables 
possibly related to birth outcomes (based 
on a priori knowledge), including maternal 
prepregnancy weight (broken stick model with 
a knot at 60 kg) (Slama and Werwatz 2005), 
maternal height (continuous), maternal smok­
ing (never, 1–5, ≥ 6 cigarettes per day), par­
ity (0, 1, ≥ 2), education level (high school 
or less, up to 2 years after high school, ≥ 3 
years after high school), gestational duration 
(linear and quadratic terms), and recruitment 
center. In addition, we adjusted for urinary 
creatinine concentration (continuous, non­
transformed) as a marker of urine dilution. 
Gestational duration was estimated using the 
date of last menstrual period (LMP) (Slama 
et al. 2008) or gestational duration assessed by 
the obstetrician if it differed from the LMP­
based estimate by > 2 weeks. Adjustment for 
the obstetrician­estimated gestational age 
instead of the LMP­based gestational age did 
not modify results (not shown). Models for 
head circumference at birth were also adjusted 
for the mode of delivery (because passage 
through the birth canal may influence head 
  circumference at birth).
We performed sensitivity analyses excluding 
women with pregnancy­induced hypertension 
(n = 17) or gestational diabetes (n = 15). All 
analyses were performed using STATA/SE, ver­
sion 11 (StataCorp, College Station, TX, USA). 
To draw our conclusion, we gave more 
weight to results in agreement with our a priori 
hypotheses, namely, an effect of BP3 and 2,5­
DCP on male birth weight (Wolff et al. 2008). 
Other associations (highlighted on the basis 
of their p­values, without relying on threshold 
p­value to define statistical significance) were 
considered as hypothesis­generating.
Results
Study population. The 287 women were 
29 years old, on average; 17% smoked dur­
ing the first trimester of pregnancy (Table 1). 
Average gestational age at delivery was 
39.8 weeks, average birth weight was 3,393 g 
(5th–95th percentiles, 2,640–4,130 g) and seven 
newborns (2%) weighed < 2,500 g. Average 
birth length was 50 cm (5th–95th percentiles, 
47–54 cm), and average head   circumference 
at birth was 35 cm (5th–95th percentiles, 
32–37 cm) (Table 1).
We detected 8 of the 11 phthalate metab­
olites and 5 of the 9 phenols in at least 95% 
of the samples (Table 2).
Phenols and birth outcomes. Birth weight 
decreased by 49 g [95% confidence interval 
(CI): –86, –13] in association with a 1­unit 
increase in ln­transformed 2,5­DCP concen­
tration. After categorizing exposures in tertiles, 
boys in the highest exposure tertile were 152 g 
lighter, on average, compared with boys in the 
lowest tertile (95% CI: –299, –5) (Table 3). 
We observed a similar association between 
2,4­DCP and birth weight [Table 3; see also 
Supplemental Material, Figure 1 (http://
dx.doi.org/10.1289/ehp.1103634)], consistent 
with the high correlation between 2,4­DCP 
and 2,5­DCP (r = 0.95). 2,5­DCP ln­trans­
formed concentration was also inversely asso­
ciated with head circumference at birth 
(–0.1 cm, 95% CI: –0.2, 0.0).
Each 1­unit increase in ln­transformed BP3 
concentration was associated with an increase of 
26 g in birth weight (95% CI: –2, 54) and of 
0.1 cm in head circumference at birth (95% CI: 
0.0, 0.2) (Table 3).
For BPA, estimates suggested an inverse 
U­shape association: birth weight increased 
by 169 g (95% CI: 14, 324) in the second 
BPA concentration tertile and by 85 g (95% 
CI: –62, 233) in the third concentration ter­
tile, compared with the first [Table 3; see Philippat et al.
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also Supplemental Material, Figure 2 (http://
dx.doi.org/10.1289/ehp.1103634) for associa­
tions based on a restricted cubic spline model]. 
BPA concentrations were positively associated 
with head circumference, which increased by 
0.8 cm in the highest BPA concentration ter­
tile compared with the lowest tertile (95% CI: 
0.2, 1.3) (Table 3).
For all other phenols, there was no evi­
dence of associations with offspring measures 
at birth [all p for heterogeneity were > 0.24 
(Table 3), and curves obtained using restricted 
cubic splines did not clearly support an asso­
ciation. See Supplemental Material, Figure 2 
(http://dx.doi.org/10.1289/ehp.1103634)].
Phthalates and birth outcomes. For phtha­
late metabolite concentrations and birth 
weight, all p for trend were > 0.14 (Table 4). 
There was some evidence of heterogene­
ity in mean birth weight across concentra­
tion tertiles for some phthalate metabolites: 
the lowest p­values for heterogeneity were 
observed for mono(3­carboxypropyl) phtha­
late (MCPP) and MECPP; given the high 
values of p for trend, results were suggestive 
of nonmonotonic associations (Table 4). For 
MECPP, but less so for MCPP, this non­
monotonic association was also supported by 
the restricted cubic spline analysis to some 
extent [see Supplemental Material, Figure 3 
(http://dx.doi.org/10.1289/ehp.1103634)].
Regarding other birth outcomes, the low­
est p­values for heterogeneity were observed 
with MCPP, monocarboxy­isooctyl phthalate 
(MCOP), monocarboxy­isononyl phthalate 
(MCNP), MEHP, and ∑HMW phthalates 
for birth length, and with ∑LMW phthalates 
for head circumference at birth (Table 4).
Sensitivity analyses. For phenols, asso­
ciations with birth outcomes remained 
similar after exclusion of 48 cases of male mal­
formations of the genitalia [See Supplemental 
Material, Table 1 (http://dx.doi.org/10.1289/
ehp.1103634)]. Using biomarker concentra­
tions not standardized for sampling conditions 
instead of concentrations standardized for sam­
pling conditions did not markedly change asso­
ciations between birth weight and, variously, 
2,4­DCP, 2,5­DCP, BP3, or BPA. Similarly, 
associations between head circumference at 
birth and either BP3 or BPA remained similar 
(see Supplemental Material, Table 1).
In analyses restricted to controls only or 
using concentrations not standardized for 
sampling conditions, findings concerning 
phthalates were consistent with those obtained 
in the main analysis, except for MECPP: The 
birth weight change observed in the second 
MECPP concentration tertile was –141 g 
(95% CI: –277, –5) in the whole study popu­
lation, –79 g (95% CI: –220, 61) after exclu­
sion of cases, and –51 g (95% CI: –187, 84) 
using nonstandardized biomarker concentra­
tions [see Supplemental Material, Table 2]. 
Table 2. Urinary phenol (n = 191) and phthalate (n = 287) biomarker concentrations after correction for 
case–control sampling (EDEN and PELAGIE cohorts, 2002–2006).
Standardized concentrations,a 
percentiles (µg/L)
Measured concentrations, 
percentiles (µg/L)
Analyte LOD (µg/L) % > LOD 5th 50th 95th 5th 50th 95th
Phenols
2,4-DCP 0.2 95.9 0.2 0.8 8.6 0.2 0.9 10.2
2,5-DCP 0.2 99.5 1.4 6.4 316.0 1.8 10.2 442.0
BPA 0.4 98.5 0.8 3.1 10.1 0.6 2.7 9.8
BP3 0.4 80.5 0.2 1.3 74.5 0.3 1.7 143.0
TCS 2.3 84.1 1.0 17.5 464.6 1.6 24.1 634.0
MP 1.0 100.0 9.0 104.3 2689.7 9.1 97.8 3520
EP 1.0 67.7 0.2 1.5 38.2 0.7 4.1 62.3
PP 0.2 96.9 0.3 10.4 267.7 0.5 12.5 402.0
BP 0.2 79.5 0.1 2.2 63.6 0.1 1.7 53.8
Phthalates
MEP 0.5 100.0 28.1 105.3 727.0 24.9 110.22 983.4
MBP 0.6 100.0 10.2 58.1 487.5 7.6 48.1 398.0
MiBP 0.3 100.0 15.6 64.7 365.3 10.9 45.9 219.0
MBzP 0.2 100.0 2.7 21.7 209.2 2.0 17.7 116.6
MCPP 0.2 98.3 0.6 3.2 13.8 0.4 2.2 10.0
MEHP 1.2 91.8 1.8 10.5 62.3 0.8 7.1 40.7
MEHHP 0.7 100 8.0 48.3 246.2 4.6 32.3 147.0
MEOHP 0.7 99.7 6.3 36.0 169.6 3.6 25.0 112.0
MECPP 0.6 100.0 18.9 67.2 303.0 11.6 43.8 183.0
MCOP 0.7 92.1 0.9 3.9 25.8 0.5 2.7 17.2
MCNP 0.6 91.8 0.9 3.1 22.8 0.6 1.7 11.7
Abbreviations: BP, butyl paraben; BPA, bisphenol A; BP3, benzophenone-3; EP, ethyl paraben; MBP, mono-n-butyl 
phthalate; MBzP, monobenzyl phthalate; MCNP, monocarboxy-isononyl phthalate; MCOP, monocarboxy-isooctyl phtha-
late; MCPP, mono(3-carboxypropyl) phthalate; MECPP, mono(2-ethyl-5-carboxypentyl) phthalate; MEHHP, mono(2-ethyl-
5-hydroxyhexyl) phthalate; MEHP, mono(2-ethylhexyl) phthalate; MEOHP, mono(2-ethyl-5-oxohexyl) phthalate; MEP, 
monoethyl phthalate; MiBP, mono-isobutyl phthalate; MP, methyl paraben; PP, propyl paraben; TCS, Triclosan; 2,4-DCP, 
2,4-dichlorophenol; 2,5-DCP, 2,5-dichlorophenol.
aConcentrations were standardized for conditions of sampling such as hour of sampling (EDEN only), time elapsed 
between sample collections and freezing, season and day of sampling, and gestational age at collection.
Table 1. Characteristics of French pregnant women and of their offspring (n = 287; EDEN and PELAGIE 
cohorts, 2002–2006).
Percentiles
Characteristic n (%) or meana 5th 50th 95th
Maternal age (years) (mean) 29.3 22 29 38
Duration of gestationb (mean) 39.7 37 40 42
Birth weight (g) (mean) 3,393 2,640 3,390 4,130
Birth length (cm) (mean) 50.1 47 50 54
Head circumference at birth (cm) (mean) 34.7 32 35 37
Gestational age at samplingb (weeks) (mean) 21.7 9 26 28
Creatinine concentration (g/L) (mean) 1.2 0.4 1.1 2.2
Parity
0 115 (40)
1 previous child 114 (40)
≥ 2 previous children 58 (20)
Maternal education
≤ High school 133 (47)
High school + 2 years 62 (22)
≥ High school + 3 years 86 (31)
Missing value 6
Active smoking
0 238 (83)
1–5 cigarettes/day 30 (11)
≥ 6 cigarettes/day 17 (6)
Missing value 2
Prepregnancy BMI (kg/m2)
< 18.5 29 (10)
18.5–25.0 181 (64)
> 25.0 73 (26)
Missing value 4
Hour of urinary sampling
Before 0800 hours 108 (65)
0800–1000 hours 40 (24)
After 1000 hours 18 (11)
Missing value 121
aSample size, unless otherwise specified. bWeeks of amenorrhea assessed by the date of the last menstrual period.Phenols, phthalates, and birth weight
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These sensitivity analyses are difficult to inter­
pret; restriction to controls decreased popu­
lation size, and standardization sometimes 
induced strong variations in the distribution 
of biomarker concentrations and hence in the 
cutoff values of tertiles.
Excluding women with pregnancy­induced 
hypertension or gestational diabetes did not 
modify our main results (data not shown).
Discussion
Within our study population of male newborns, 
maternal urinary concentrations of 2,4­DCP 
and 2,5­DCP were associated with a birth 
weight decrease, whereas urinary concentrations 
of BP3 were positively associated with weight 
and head circumference at birth. BPA urinary 
concentrations were positively associated with 
head circumference. There was no evidence 
of monotonic associations between phthalate 
metabolite concentrations and birth weight.
Phenols and birth outcomes. In our study 
population, birth weight decreased by 152 g in 
the highest 2,5­DCP concentration tertile com­
pared with the lowest tertile (95% CI: –299, 
–5). The only other human study addressing 
this issue reported a decrease by 210 g in the 
third 2,5­DCP concentration tertile compared 
Table 3. Adjusted associations between maternal urinary concentrations of phenol biomarkers standardized for sampling conditionsa and birth outcomes (EDEN 
cohort, 2003–2006). 
Analyte (µg/L)a
Changeb in birth weight 
n = 191
Changeb in birth length 
n = 190
Changeb in head circumference  
n = 189
β (g) (95% CI) phet
c ptrend
d β (cm) (95% CI) phet
c ptrend
d β (cm) (95% CI) phet
c ptrend
d
2,4-DCP
< 0.6 0 < 0.01 < 0.01 0 0.09 0.77 0 < 0.01 0.01
0.6–1.3 24 (–129, 177) 0.7 (0.1, 1.3) 0.8 (0.2, 1.4)
≥ 1.3 –181 (–323, –40) 0.2 (–0.5, 0.9) –0.3 (–0.8, 0.3)
Ln(2,4-DCP) –77 (–129, –25) –0.1 (–0.4, 0.2) –0.1 (–0.3, 0.1)
2,5-DCP
< 3.9 0 0.10 0.03 0 0.53 0.70 0 0.14 0.10
3.9–13.9 –49 (–206, 108) 0.4 (–0.3, 1.0) –0.3 (–0.8, 0.3)
≥ 13.9 –152 (–299, –5) 0.3 (–0.4, 1.0) –0.5 (–1.1, 0.0)
Ln(2,5-DCP) –49 (–86, –13) 0.0 (–0.2, 0.2) –0.1 (–0.2, 0.0)
BPA
< 2.2 0 0.10 0.70 0 0.98 0.83 0 0.04 0.01
2.2–4.7 169 (14, 324) 0.0 (–0.7, 0.8) 0.3 (–0.3, 0.9)
≥ 4.7 85 (–62, 233) 0.1 (–0.7, 0.9) 0.8 (0.2, 1.3)
Ln(BPA) –9 (–98, 80) 0.0 (–0.4, 0.4) 0.3 (0.0, 0.7)
BP3
< 0.7 0 0.20 0.09 0 0.17 0.14 0 0.12 0.04
0.7–2.7 –15 (–155, 124) –0.3 (–1.0, 0.3) 0.2 (–0.5, 0.8)
≥ 2.7 105 (–40, 250) 0.4 (–0.3, 1.0) 0.5 (0.0, 1.0)
Ln(BP3) 26 (–2, 54) 0.1 (–0.1, 0.2) 0.1 (0.0, 0.2)
TCS
< 4.5 0 0.68 0.79 0 0.68 0.59 0 0.31 0.18
4.5–51.3 –58 (–194, 78) –0.2 (–0.9, 0.4) 0.2 (–0.3, 0.7)
≥ 51.3 –40 (–171, 90) 0.1 (–0.6, 0.7) –0.2 (–0.7, 0.3)
Ln(TCS) –6 (–31, 19) 0.0 (–0.1, 0.1) –0.1 (–0.2, 0.0)
MP
< 62.8 0 0.75 0.58 0 0.47 0.23 0 0.79 0.58
62.8–213.0 –32 (–168, 105) 0.2 (–0.5, 0.8) 0.2 (–0.4, 0.7)
≥ 213.0 24 (–121, 168) 0.4 (–0.3, 1.2) 0.2 (–0.4, 0.8)
Ln(MPB) –2 (–37, 34) 0.1 (–0.1, 0.3) 0.0 (–0.1, 0.2)
EP
< 0.6 0 0.98 0.86 0 0.24 0.97 0 0.47 0.94
0.6–3.7 10 (–129, 148) 0.6 (–0.1, 1.3) 0.4 (–0.2, 1.0)
≥ 3.7 17 (–145, 178) 0.3 (–0.4, 0.9) 0.2 (–0.4, 0.8)
Ln(EPB) –1 (–43, 41) 0.1 (–0.1, 0.3) 0.1 (–0.1, 0.3)
PP
< 4.7 0 1.00 0.95 0 0.98 0.93 0 0.52 0.62
4.7 – 24.8 –2 (–137, 132) –0.1 (–0.7, 0.6) –0.3 (–0.8, 0.2)
≥ 24.8 –5 (–151, 140) 0.2 (–0.8, 0.7) –0.2 (–0.8, 0.3)
Ln(PPB) –10 (–40, 19) 0.0 (–0.2, 0.2) –0.1 (–0.2, 0.1)
BP
< 0.6 0 0.97 0.95 0 0.58 0.49 0 0.61 0.45
0.6 – 6.8 –15 (–156, 126) 0.2 (–0.5, 1.0) 0.2 (–0.3, 0.7)
≥ 6.8 –2 (–155, 150) –0.1 (–0.9, 0.7) 0.3 (–0.3, 0.8)
Ln(BPB) –1 (–32, 29) 0.0 (–0.2, 0.2) 0.1 (–0.1, 0.2)
∑PB (µmol/L)
< 0.5 0 0.95 0.86 0 0.61 0.38 0 0.80 0.66
0.5 – 1.6 –16 (–150, 118) 0.2 (–0.4, 0.9) 0.2 (–0.4, 0.7)
≥ 1.6 6 (–143, 156) 0.4 (–0.4, 1.1) 0.2 (–0.4, 0.7)
Ln(∑PB) –3 (–39, 33) 0.1 (–0.1, 0.3) 0.0 (–0.2, 0.1)
Abbreviations: BP, butyl paraben; BPA, bisphenol A; BP3, benzophenone-3; MP, methyl paraben; EP, ethyl paraben; PP, propyl paraben; TCS, Triclosan; 2,4-DCP, 2,4-dichlorophenol; 2,5-DCP, 
2,5-dichlorophenol; ∑PB, molecular sum of parabens. Regression models were corrected for the overrepresentation of cases of malformations of the genitalia by a weighting approach.
aConcentrations were standardized for conditions of sampling such as hour of sampling, time elapsed between sample collections and freezing, season and day of sampling, and gesta-
tional age at collection. bAdjusted for gestational duration, maternal prepregnancy weight and height, maternal smoking, maternal education level, parity, recruitment center, and crea-
tinine level. Models for head circumference at birth were also adjusted for mode of delivery (cesarean section yes/no). cp-Values of heterogeneity test. dp-Values of monotonic trend test.Philippat et al.
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with the first (95% CI: –348, –71) (Wolff 
et al. 2008). Concentrations of 2,5­DCP 
(and hence tertiles) were much higher in the 
study by Wolff et al. (median, 53 µg/L) than 
in ours (median standardized concentration, 
6.4 µg/L). Wolff et al. also reported that boys 
were 0.3 cm shorter at birth per increase by 
1 in ln(2,5­DCP) (95% CI: –0.6, –0.4). Our 
results did not clearly support such an associa­
tion (0.0 cm per increase by 1 in ln(2,5­DCP); 
95% CI: –0.2, 0.2), but birth length is not very 
accurately assessed, implying potentially strong 
measurement error. 2,5­DCP is a metabolite of 
1,4­dichlorobenzene, which is used as chem­
ical intermediate in the production of dyes 
and organic chemicals and found in mothballs 
and toilet­deodorizer blocks (Agency for Toxic 
Substances and Disease Registry 2006; Yoshida 
et al. 2002). Dichlorophenols may also be 
released from water treatments (Abrahamsson 
and Xie 1983).
2,4­DCP was also associated with a birth 
weight decrease. It is a metabolite of 1,3­di­
cholorobenzene, a minor contaminant of 1,4­
dichlorobenzene (Agency for Toxic Substances 
and Disease Registry 2006; Yoshida et al. 
2002), which may explain the high correla­
tion reported between concentrations of both 
DCPs. 2,4­DCP is also an environmental trans­
formation intermediate of the antiseptic agent 
triclosan and of herbicides such as 2,4­dichloro­
phenoxyacetic acid and 2­(2,4­dichloro­
phenoxy) propionic acid (Yang et al. 2010; 
Zona et al. 2002). Our results concerning 
2,4­DCP are difficult to compare with those 
of Wolff et al. (2008), who studied male and 
female newborns altogether for this compound.
Taken together, these studies suggest an 
effect of dichlorophenols, or one of their pre­
cursors, on birth weight.
BP3 urinary concentrations were positively 
associated with weight and head circumference 
at birth. Boys were 105 g heavier (95% CI: 
–40, 250) in the highest BP3 concentration ter­
tile compared with the lowest. Similarly, Wolff 
et al. (2008) noted a birth weight increase in 
male infants in the highest BP3 concentration 
tertile compared with the lowest (betas not 
reported); they did not report effect estimates 
for BP3 and head circumference in males. 
Exposure to BP3 likely results from use of 
consumer products as sunscreens or cosmetics 
(Calafat et al. 2008).
BPA urinary concentrations were posi­
tively associated with head circumference 
at birth. After categorizing exposures in ter­
tiles, we observed an inverse U­shape asso­
ciation between BPA concentrations and birth 
weight. Such nonmonotonic dose–response 
curves between perinatal exposures to BPA 
and weight in early life have been reported in 
rodents (Rubin et al. 2001; Rubin and Soto 
2009). However, urinary BPA concentrations 
Table 4. Adjusted associations between maternal urinary concentrations of phthalate biomarkers standardized for sampling conditionsa and birth outcomes 
(EDEN and PELAGIE cohorts, 2002–2006). 
Changeb in birth weight 
n = 287
Changeb in birth length 
n = 286
Changeb in head circumference  
n = 285
Analytes (µg/L)a β (g) (95% CI) phet
c ptrend
d β (cm) (95% CI) phet
c ptrend
d β (cm) (95% CI) phet
c ptrend
d
MEP
< 113.8 0 0.61 0.60 0 0.22 0.58 0 0.32 0.14
113.8–275.7 46 (–102, 194) 0.5 (–0.2, 1.1) 0.2 (–0.3, 0.7)
≥ 275.7 –14 (–162, 133) 0.0 (–0.6, 0.7) 0.4 (–0.1, 1.0)
 Ln(MEP) 3 (–51, 57) 0.0 (–0.3, 0.2) 0.1 (–0.2, 0.3)
MBP
< 45.6 0 0.44 0.42 0 0.69 0.91 0 0.89 0.63
45.6–85.5 52 (–101, 206) 0.3 (–0.4, 0.9) 0.1 (–0.5, 0.6)
≥ 85.5 –30 (–174, 114) 0.1 (–0.6, 0.7) 0.1 (–0.4, 0.7)
 Ln(MBP) –13 (–61, 35) 0.1 (–0.2, 0.3) 0.0 (–0.2, 0.2)
MiBP
< 48.2 0 0.41 0.48 0 0.46 0.54 0 0.50 0.40
48.2–97.9 61 (–77, 200) 0.4 (–0.3, 1.1) –0.1 (–0.6, 0.4)
≥ 97.9 –31 (–190, 129) 0.3 (–0.4, 1.0) 0.2 (–0.5, 0.9)
 Ln(MiBP) –44 (–110, 23) 0.0 (–0.3, 0.3) –0.1 (–0.4, 0.1)
MCPP
< 2.1 0 0.03 0.73 0 0.03 0.55 0 0.20 0.77
2.1–4.4 –198 (–343, –52) –0.7 (–1.4, –0.1) –0.5 (–0.1, 0.1)
≥ 4.4 –95 (–243, 52) –0.1 (–0.8, 0.7) –0.3 (–0.9, 0.4)
 Ln(MCPP) –34 (–91, 22) 0.1 (–0.2, 0.4) –0.2 (–0.4, 0.1)
MBzP
< 17.6 0 0.67 0.43 0 0.99 0.88 0 0.55 0.32
17.6–57.2 14 (–141, 170) 0.0 (–0.7, 0.7) –0.2 (–0.8, 0.4)
≥ 57.2 –50 (–223, 123) 0.1 (–0.9, 0.7) –0.3 (–0.9, 0.3)
 Ln(MBzP) –23 (–71, 24) 0.1 (–0.3, 0.2) 0.0 (–0.2, 0.2)
MEHP
< 6.8 0 0.20 0.93 0 0.12 0.69 0 0.55 0.56
6.8–17.1 –122 (–261, 17) –0.6 (–1.2, 0.0) –0.2 (–0.7, 0.3)
≥ 17.1 –37 (–184, 110) –0.3 (–0.9, 0.3) 0.1 (–0.5, 0.6)
Ln(MEHP) 1 (–60, 62) 0.0 (–0.3, 0.2) 0.0 (–0.2, 0.2)
MEOHP
< 25.2 0 0.42 0.28 0 0.33 0.27 0 0.94 .75
25.2–56.8 –37 (–179, 105) –0.2 (–0.8, 0.4) 0.0 (–0.5, 0.6)
≥ 56.8 60 (–89, 209) 0.3 (–0.4, 1.0) –0.1 (–0.6, 0.5)
 Ln(MEOHP) 5 (–56, 66) 0.1 (–0.2, 0.3) 0.0 (–0.3, 0.2)
MEHHP
< 32.2 0 0.58 0.65 0 0.61 0.80 0 0.88 0.76
32.2–77.9 –60 (–202, 81) –0.3 (–0.9, 0.4) –1.0 (–0.6, 0.4)
≥ 77.9 7 (–139, 154) 0.0 (–0.7, 0.7) –0.1 (–0.7, 0.4)
 Ln(MEHHP) 4 (–54, 62) 0.1 (–0.2, 0.3) 0.0 (–0.2, 0.2)
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were relatively low in our study population, 
enhancing the analytical uncertainties and 
hence the potential for exposure misclassifica­
tion, which may limit our ability to distinguish 
monotonic from nonmonotonic associations.
Phthalates and birth outcomes. There was 
no strong evidence of monotonic association 
between phthalate metabolite concentrations 
and birth outcomes, except for the possible 
positive association between MCNP and birth 
length. Our analyses suggested nonmonotonic 
associations with birth weight and birth length 
for some phthalate metabolites. To our knowl­
edge, such associations between phthalate 
metabolites and birth weight have not been 
reported previously in rodents or in humans 
and therefore should be considered cautiously.
Study population. To correct the overrepre­
sentation of cases induced by our case–control 
design, we weighted the observations in regres­
sion models (Richardson et al. 2007). We also 
performed nonweighted analyses, restricted to 
controls, and our main results regarding birth 
weight remained similar to those based on the 
whole weighted study population.
Exposure assessment. Sampling con­
ditions, such as hour of urine sampling or 
storage duration before freezing, may influ­
ence the concentrations of several biomarkers 
(Mahalingaiah et al. 2008; Samandar et al. 
2009). We used a two­step standardization 
method based on regression residuals to 
reduce undesirable variability in biomarker 
urinary concentrations due to sampling con­
ditions. To our knowledge, it is the first time 
that such an approach has been applied to 
study associations between phthalate or phe­
nol prenatal exposures and birth outcomes. 
We repeated our analyses using concentra­
tions not standardized for sampling condi­
tions, and associations between DCPs or BP3 
and birth weight or between BP3 and BPA 
and head circumference were similar.
Limitations. The assayed phenols and 
phthalates and their metabolites have relatively 
short half­lives in humans (typically ≤ 1 day), 
but accurate information is not available 
on half­lives in pregnant women, in whom 
metabolism may differ compared with non­
pregnant women. We assessed exposures from 
the urinary concentrations at a single point 
during pregnancy; increasing the number of 
urine samples collected would have provided 
a more accurate estimate of the average expo­
sure during the whole gestation. Adibi et al. 
(2008) reported that for phthalates, the prob­
ability of correctly classifying a woman into 
a low­exposure group based on a single urine 
sample, if she truly had low exposure based 
on multiple measurements, was between 0.43 
for monoethyl phthalate (MEP) and 0.95 for 
mono­isobutyl phthalate (MiBP). Concerning 
phenols, BPA concentrations also vary dur­
ing pregnancy (Braun et al. 2011). Therefore, 
clearly there is exposure misclassification, 
whose amplitude differs according to the bio­
logically relevant exposure window (if any) 
and the compound considered.
We adjusted for many potential con­
founders, but residual confounding cannot 
be discarded. For example, specific metabolic 
disorders associated with both fetal growth 
and xenobiotic metabolism would constitute 
potential confounders. In our study, excluding 
women with pregnancy­induced hypertension 
Table 4. continued
Changeb in birth weight 
n = 287
Changeb in birth length 
n = 286
Changeb in head circumference 
n = 285
Analytes (µg/L)a β (g) (95% CI) phet
c ptrend
d β (cm) (95% CI) phet
c ptrend
d β (cm) (95% CI) phet
c ptrend
d
MECPP
< 45.8 0 0.08 0.59 0 0.40 0.43 0 0.90 0.65
45.8–105.4 –141 (–277, –5) –0.3 (–1.0, 0.4) 0.0 (–0.5, 0.6)
≥ 105.4 –20 (–162, 121) 0.2 (–0.6, 0.9) 0.1 (–0.4, 0.6)
 Ln(MECPP) 5 (–64, 73) 0.1 (–0.2, 0.4) 0.0 (–0.2, 0.3)
MCOP
< 2.4 0 0.87 0.87 0 0.11 0.19 0 0.77 0.79
2.4–5.9 –40 (–192, 110) –0.2 (–0.9, 0.4) –0.1 (–0.7, 0.4)
≥ 5.9 –27 (–200, 147) 0.4 (–0.5, 1.2) 0.0 (–0.6, 0.6)
Ln(MCOP) –8 (–72, 55) 0.1 (–0.2, 0.4) 0.0 (–0.2, 0.3)
MCNP
< 2.3 0 0.85 0.99 0 0.11 0.08 0 0.89 0.72
2.3–4.6 –40 (–186, 107) 0.5 (–0.1, 1.2) –0.1 (–0.7, 0.4)
≥ 4.6 –15 (–189, 158) 0.9 (0.0, 1.7) –0.1 (–0.8, 0.5)
 Ln(MCNP) –3 (–67, 61) 0.3 (–0.1, 0.6) –0.1 (–0.3, 0.1)
DEHP (µmol/L)
< 0.4 0 0.43 0.29 0 0.18 0.39 0 0.80 0.68
0.4–0.9 –54 (–197, 88) –0.4 (–1.0, 0.2) 0.1 (–0.3, 0.6)
≥ 0.9 36 (–112, 186) 0.1 (–0.6, 0.9) 0.2 (–0.4, 0.7)
 Ln(DEHP) 5 (–60, 70) 0.1 (–0.2, 0.4) 0.0 (–0.2, 0.2)
∑LMW (µmol/L)
< 1.2 0 0.32 0.14 0 0.29 0.53 0 0.12 0.52
1.2–2.7 –3 (–141, 135) 0.4 (–0.2, 1.1) 0.5 (0.0, 0.9)
≥ 2.7 –100 (–248, 47) 0.0 (–0.7, 0.7) 0.4 (–0.3, 1.0)
 Ln(∑LMW) –38 (–109, 34) –0.1 (–0.4, 0.2) –0.1 (–0.4, 0.2)
∑HMW (µmol/L)
< 0.5 0 0.17 0.37 0 0.06 0.26 0 0.82 0.54
0.5–1.3 –99 (–243, 44) –0.5 (–1.2, 0.1) 0.0 (–0.5, 0.5)
≥ 1.3 19 (–161, 198) 0.2 (–0.6, 1.0) 0.2 (–0.5, 0.8)
 Ln(∑HMW) –2 (–70, 65) 0.1 (–0.2, 0.4) 0.0 (–0.2, 0.2)
Abbreviations: MBP, mono-n-butyl phthalate; MBzP, monobenzyl phthalate; MCNP, monocarboxyisononyl phthalate; MCOP, monocarboxy-isooctyl phthalate; MCPP, mono(3-carboxy-
propyl) phthalate; MECPP, mono(2-ethyl-5-carboxypentyl) phthalate; MEHP, mono(2-ethylhexyl) phthalate; MEHHP, mono(2-ethyl-5-hydroxyhexyl) phthalate; MEOHP, mono(2-ethyl-5-
oxohexyl) phthalate; MEP, monoethyl phthalate; MiBP, mono-isobutyl phthalate. DEHP, molecular sum of 4 metabolites of di(2-ethylhexyl) phthalate (MEHP, MEHHP, MEOHP, MECPP); 
∑LMW, molecular sum of low-MW phthalates (MEP, MBP, and MiBP); ∑HMW, molecular sum of high-MW phthalates (MBzP, MCPP, MEHP, MECPP, MEHHP, MEOHP, MCOP, and 
MCNP). Regression models were corrected for the overrepresentation of cases of malformations of the genitalia by a weighting approach.
aConcentrations were standardized for conditions of sampling such as hour of sampling (EDEN only), time elapsed between sample collections and freezing, season and day of sam-
pling, and gestational age at collection. bAdjusted for gestational duration, maternal prepregnancy weight and height, maternal smoking, maternal education level, parity, recruitment 
center, and urine dilution (creatinine level). Models for head circumference at birth were also adjusted for mode of delivery (cesarean section yes/no). cp-Values of heterogeneity test. 
dp-Values of monotonic trend test.Philippat et al.
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or gestational diabetes did not alter associations 
with BPA and BP3 (not shown). Multiple 
comparisons are generally an issue in studies 
relying on several biomarkers. Although we 
did not formally correct for multiple compari­
sons, our choice to focus our conclusions on 
previously reported associations limits the risk 
of chance being a likely explanation for our 
main findings.
Conclusions
In our study, there was no strong evidence 
of monotonic association between phthalate 
metabolite concentrations and birth out­
comes. Urinary concentrations of 2,4­DCP 
and 2,5­DCP were negatively associated with 
birth weight, whereas BP3 concentrations 
were associated with a birth weight increase. 
Results concerning 2,5­DCP and BP3 are in 
agreement with another publication concern­
ing male newborns from New York (Wolff 
et al. 2008).
co r r e c t i o n
In Table 2, monoethyl phthalate (MEP) 
and monobenzyl phthalate (MBzP) con­
centrations have been corrected [multi­
plied by 0.66 (MEP) and 0.72 (MBzP)] 
because the analytical standards used were 
of   inadequate purity.
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